ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.
AstraZeneca’s Duo-O trial suggests that excluding Brca-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer.